^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IMJ995

    i
    Other names: IMJ995
    Associations

    News

    Trials
    Company:
    Novartis
    Drug class:
    CD19-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    over1year
    CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=0, Withdrawn, Novartis Pharmaceuticals | N=35 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD19 expression
    |
    IMJ995
    over1year
    Study of IMJ995 in kids and adults with Acute Lymphoblastic Leukemia (clinicaltrialsregister.eu)
    P1, N=35, Novartis Pharma AG
    New P1 trial
    |
    CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD19 expression
    |
    IMJ995
    over1year
    CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=35, Not yet recruiting, Novartis Pharmaceuticals | Trial completion date: Mar 2026 --> Jul 2026 | Trial primary completion date: Mar 2026 --> Jul 2026
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD19 expression
    |
    IMJ995
    almost2years
    CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=35, Not yet recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2025 --> Mar 2026 | Initiation date: Sep 2022 --> Dec 2022 | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial completion date • Trial initiation date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD19 expression
    |
    IMJ995
    2years
    CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=35, Not yet recruiting, Novartis Pharmaceuticals | Trial completion date: Jul 2025 --> Oct 2025 | Initiation date: Mar 2022 --> Jul 2022 | Trial primary completion date: Jul 2025 --> Oct 2025
    Trial completion date • Trial initiation date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD19 expression
    |
    IMJ995
    over2years
    CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=35, Not yet recruiting, Novartis Pharmaceuticals
    New P1 trial • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD19 expression
    |
    IMJ995